HIF-2α deletion promotes Kras-driven lung tumor development

被引:108
|
作者
Mazumdar, Jolly [1 ,5 ]
Hickey, Michele M. [1 ,2 ]
Pant, Dhruv K. [1 ,3 ]
Durham, Amy C. [6 ]
Sweet-Cordero, Alejandro [7 ]
Vachani, Anil [8 ]
Jacks, Tyler [9 ]
Chodosh, Lewis A. [1 ,3 ]
Kissil, Joseph L. [10 ]
Simon, M. Celeste [1 ,4 ,5 ]
Keith, Brian [1 ,3 ]
机构
[1] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA
[5] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA
[7] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[8] Abramson Res Ctr, Philadelphia, PA 19104 USA
[9] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[10] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
hypoxia; inducible mouse model; non-small cell lung cancer; tumor suppressor; GENE-EXPRESSION; NORMAL-1; HIN-1; FREQUENT EVENT; HYPOXIA; CANCER; GROWTH; HIF-1; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; METHYLATION; HIF-1-ALPHA;
D O I
10.1073/pnas.1001296107
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. The oxygen-sensitive hypoxia inducible factor (HIF) transcriptional regulators HIF-1 alpha and HIF-2 alpha are overexpressed in many human NSCLCs, and constitutive HIF-2 alpha activity can promote murine lung tumor progression, suggesting that HIF proteins may be effective NSCLC therapeutic targets. To investigate the consequences of inhibiting HIF activity in lung cancers, we deleted Hif-1 alpha or Hif-2 alpha in an established Kras(G12D)-driven murine NSCLC model. Deletion of Hif-1 alpha had no obvious effect on tumor growth, whereas Hif-2 alpha deletion resulted in an unexpected increase in tumor burden that correlated with reduced expression of the candidate tumor suppressor gene Scgb3a1 (HIN-1). Here, we identify Scgb3a1 as a direct HIF-2 alpha target gene and demonstrate that HIF-2 alpha regulates Scgb3a1 expression and tumor formation in human KrasG12D-driven NSCLC cells. AKT pathway activity, reported to be repressed by Scgb3a1, was enhanced in HIF-2 alpha-deficient human NSCLC cells and xenografts. Finally, a direct correlation between HIF-2 alpha and SCGB3a1 expression was observed in approximately 70% of human NSCLC samples analyzed. These data suggest that, whereas HIF-2 alpha overexpression can contribute to NSCLC progression, therapeutic inhibition of HIF-2 alpha below a critical threshold may paradoxically promote tumor growth by reducing expression of tumor suppressor genes, including Scgb3a1.
引用
收藏
页码:14182 / 14187
页数:6
相关论文
共 50 条
  • [31] The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
    Valencia, Karmele
    Erice, Oihane
    Kostyrko, Kaja
    Hausmann, Simone
    Guruceaga, Elizabeth
    Tathireddy, Anuradha
    Flores, Natasha M.
    Sayles, Leanne C.
    Lee, Alex G.
    Fragoso, Rita
    Sun, Tian-Qiang
    Vallejo, Adrian
    Roman, Marta
    Entrialgo-Cadierno, Rodrigo
    Migueliz, Itziar
    Razquin, Nerea
    Fortes, Puri
    Lecanda, Fernando
    Lu, Jun
    Ponz-Sarvise, Mariano
    Chen, Chang-Zheng
    Mazur, Pawel K.
    Sweet-Cordero, E. Alejandro
    Vicent, Silvestre
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04): : 1879 - 1895
  • [32] Opening a New GATAway for Treating KRAS-Driven Lung Tumors
    Barbacid, Mariano
    CANCER CELL, 2012, 21 (05) : 598 - 600
  • [33] Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
    Sangodkar, Jaya
    Perl, Abbey
    Tohme, Rita
    Kiselar, Janna
    Kastrinsky, David B.
    Zaware, Nilesh
    Izadmehr, Sudeh
    Mazhar, Sahar
    Wiredja, Danica D.
    O'Connor, Caitlin M.
    Hoon, Divya
    Dhawan, Neil S.
    Schlatzer, Daniela
    Yao, Shen
    Leonard, Daniel
    Borczuk, Alain C.
    Gokulrangan, Giridharan
    Wang, Lifu
    Svenson, Elena
    Farrington, Caroline C.
    Yuan, Eric
    Avelar, Rita A.
    Stachnik, Agnes
    Smith, Blake
    Gidwani, Vickram
    Giannini, Heather M.
    McQuaid, Daniel
    McClinch, Kimberly
    Wang, Zhizhi
    Levine, Alice C.
    Sears, Rosalie C.
    Chen, Edward Y.
    Duan, Qiaonan
    Datt, Manish
    Haider, Shozeb
    Ma'ayan, Avi
    DiFeo, Analisa
    Sharma, Neelesh
    Galsky, Matthew D.
    Brautigan, David L.
    Ioannou, Yiannis A.
    Xu, Wenqing
    Chance, Mark R.
    Ohlmeyer, Michael
    Narla, Goutham
    JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (06): : 2081 - 2090
  • [34] Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
    Bhatt, Vrushank
    Lan, Taijin
    Wang, Wenping
    Kong, Jerry
    Lopes, Eduardo Cararo
    Wang, Jianming
    Khayati, Khoosheh
    Raju, Akash
    Rangel, Michael
    Lopez, Enrique
    Hu, Zhixian Sherrie
    Luo, Xuefei
    Su, Xiaoyang
    Malhotra, Jyoti
    Hu, Wenwei
    Pine, Sharon R.
    White, Eileen
    Guo, Jessie Yanxiang
    CELL DEATH & DISEASE, 2023, 14 (01)
  • [35] Inhibition of Autophagy and MEK Promotes Ferroptosis in Lkb1-Deficient Kras-Driven Lung Tumors
    Bhatt, Vrushank
    Lan, Taijin
    Wang, Wenping
    Kong, Jerry
    Lopes, Eduardo Cararo
    Khayati, Khoosheh
    Wang, Jianming
    Raju, Akash
    Rangel, Michael
    Lopez, Enrique
    Hu, Zhixian Sherrie
    Luo, Xuefei
    Su, Xiaoyang
    White, Eileen
    Guo, Jessie Yanxiang
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [36] Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
    Vrushank Bhatt
    Taijin Lan
    Wenping Wang
    Jerry Kong
    Eduardo Cararo Lopes
    Jianming Wang
    Khoosheh Khayati
    Akash Raju
    Michael Rangel
    Enrique Lopez
    Zhixian Sherrie Hu
    Xuefei Luo
    Xiaoyang Su
    Jyoti Malhotra
    Wenwei Hu
    Sharon R. Pine
    Eileen White
    Jessie Yanxiang Guo
    Cell Death & Disease, 14
  • [37] CRAF dimerization with ARAF regulates KRAS-driven tumor growth
    Venkatanarayan, Avinashnarayan
    Liang, Jason
    Yen, Ivana
    Shanahan, Frances
    Haley, Benjamin
    Phu, Lilian
    Verschueren, Erik
    Hinkle, Trent B.
    Kan, David
    Segal, Ehud
    Long, Jason E.
    Lima, Tony
    Liau, Nicholas P. D.
    Sudhamsu, Jawahar
    Li, Jason
    Klijn, Christiaan
    Piskol, Robert
    Junttila, Melissa R.
    Shaw, Andrey S.
    Merchant, Mark
    Chang, Matthew T.
    Kirkpatrick, Donald S.
    Malek, Shiva
    CELL REPORTS, 2022, 38 (06):
  • [38] TRIM58 is a prognostic biomarker remodeling tumor microenvironment in KRAS-driven lung adenocarcinoma
    Chen, Xiaowei
    Wang, Yu
    Qu, Xiao
    Bie, Fenglong
    Wang, Yadong
    Du, Jiajun
    FUTURE ONCOLOGY, 2021, 17 (05) : 565 - 579
  • [39] Arf suppresses the growth and progression of Kras-driven lung tumors
    Busch, Stephanie E.
    Gurley, Kay E.
    Moser, Russell D.
    Kelly-Spratt, Karen S.
    Kemp, Christopher J.
    CANCER RESEARCH, 2011, 71
  • [40] Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
    Wang, Dong
    Cong, Jingjing
    Fu, Binqing
    Zheng, Xiaohu
    Sun, Rui
    Tian, Zhigang
    Wei, Haiming
    CANCER LETTERS, 2020, 492 : 31 - 43